Body Handbook Catalogue Profile Ranking
Gut BODY HANDBOOK
Gut ยท ยง77
Microbiome Drugs for C. diff
If you have had C. diff come back twice, the odds it comes back again pass 60% Guh 2020. Antibiotics keep failing because they are the trigger: they clear the infection and the protective gut community in one sweep, leaving the colon empty for the next round. Two FDA-approved live biotherapeutics, Rebyota and Vowst, put that community back and break the loop in roughly 9 of 10 patients. Ask about them by name once you have had two or more episodes.
Decide ยท Course Evidence Moderate Chapter Gut

A healthy colon is packed with bacteria that starve out C. difficile and keep its spores from waking up. Broad-spectrum antibiotics flatten that community; the drugs used to treat C. diff itself, vancomycin and fidaxomicin, finish the job. When the course ends, leftover spores recolonize an empty colon, the diarrhea returns, and another course of antibiotics locks the cycle in tighter 1. The live biotherapeutics deliver the missing community back: Rebyota as a donor-stool slurry, Vowst as the spore-only fraction left after an ethanol wash 2 3.

The numbers hold across trials. In Vowst's pivotal trial, recurrence at eight weeks was 12.4% versus 39.8% on placebo 4. Pooled across its phase 3 studies, about 9 in 10 stayed clear at eight weeks and roughly 85 in 100 held through six months 5. Rebyota lands in the same range 6. Older fecal transplant does too, at around 80 to 85 percent per procedure 7, so the 2024 guideline puts all three on the table for two-or-more recurrences 8.

This is a prescription decision, so bring it to the clinician yourself.

The arc after a working treatment:

  • One to two weeks: stools normalize and stay normal. You stop scouting for bathrooms and sleep through the night.
  • Four to eight weeks: energy, appetite, and weight come back as your gut absorbs food again.
  • Six months: roughly 85 to 90 percent of treated patients are still recurrence-free 6 5.
The fine print โ€” when to skip it, and what people get wrong
  • "It treats the infection." No. It only prevents recurrence; antibiotics still clear the active episode first.
  • "It's a fancy probiotic." No. Over-the-counter probiotics don't prevent recurrent C. diff; these are screened donor-stool biologics.

Made from human donor stool: donors are screened, but the label warns of residual infection risk, traced to a 2019 case under looser rules 9. Severe immunosuppression and pregnancy were trial-excluded and need a specialist's call.

References
  1. 1Guh et al. (2020). Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes. New England Journal of Medicine. link
  2. 2FDA (2022). FDA Approves First Fecal Microbiota Product (Rebyota). link
  3. 3FDA (2023). FDA Approves First Orally Administered Fecal Microbiota Product for the Prevention of Recurrence of Clostridioides difficile Infection (Vowst). link
  4. 4Feuerstadt et al. (2022). SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. New England Journal of Medicine. link
  5. 5Khanna et al. (2024). Integrated efficacy analysis from phase 3 studies of investigational microbiome therapeutic, SER-109, in recurrent Clostridioides difficile infection. Therapeutic Advances in Gastroenterology. link
  6. 6Khanna et al. (2022). Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection. Drugs. link
  7. 7Quraishi et al. (2017). Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Alimentary Pharmacology & Therapeutics. link
  8. 8Peery et al. (2024). AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases. Gastroenterology. link
  9. 9FDA (2020). Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Events Likely Due to Transmission of Pathogenic Organisms. link
Related in the handbook (5)
Undermines
  • โ€” Broad antibiotics like the fluoroquinolones are a leading trigger for the C. diff cycle these drugs exist to break. Skipping a needless course is prevention.
Alternatives
  • โ€” FMT and these newer FDA-approved live biotherapeutics are the same idea; the products are the regulated version.
Related
  • โ€” Repeated antibiotic courses are how people end up in the C. diff relapse cycle these products are built to break.
  • โ€” If diarrhoea won't quit, recurrent C. diff is one treatable cause โ€” and re-seeding the gut ends the loop in nine of ten.
  • โ€” Ordinary probiotics won't fix recurrent C. diff โ€” these are the heavy-duty, whole-community version that does.
ยท
77